Shilpa rallied 14% on Monday after it entered into a 3-year firm agreement with Dr. Reddy’s Laboratories for production and supply of Russian Sputnik-V vaccine. Shilpa targets to produce 50 million doses of Component 1 and 50 million doses of Component 2 on behalf of DRL at its Dharwad facility. They are exploring Sputnik Light, a single dose vaccine.
Shilpa rallied 14% on Monday after it entered into a 3-year firm agreement with Dr. Reddy’s Laboratories for production and supply of Russian Sputnik-V vaccine. Shilpa targets to produce 50 million doses of Component 1 and 50 million doses of Component 2 on behalf of DRL at its Dharwad facility. They are exploring Sputnik Light, a single dose vaccine.